News - Vivalis, Genetics

Filter

Current filters:

VivalisGenetics

Popular Filters

1 to 25 of 28 results

NicOx appoints financial partner to assess Duchenne Muscular Dystrophy treatment

14-02-2014

French biotechnology firm NicOx (Euronext Paris: COX) has granted an undisclosed financial partner an…

BiotechnologyFranceGeneticsLicensingnaproxcinodNicOx

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

Ipsen’s Dysport next generation shows safety and efficacy in Phase III

05-02-2014

French drugmaker Ipsen today announced the results of the international Phase III clinical trial of Dysport…

DysportFranceGeneticsIpsenPharmaceuticalResearch

UCB launches online search for rare phenotypes

UCB launches online search for rare phenotypes

28-01-2014

Belgian drugmaker UCB (Euronext Brussels: UCB) has launched an online search to find rare phenotypes…

GeneticsGlobalPharmaceuticalRare diseasesResearchUCB

Nuevolution signs licensing agreement with Novartis

Nuevolution signs licensing agreement with Novartis

10-01-2014

Denmark-based Nuevolution has entered into a non-exclusive technology licensing agreement with Swiss…

BiotechnologyDenmarkGeneticsLicensingNorthern EuropeNovartisNuevolutionResearch

Scotland demonstrates its collaborative approach to cell therapy development

Scotland demonstrates its collaborative approach to cell therapy development

14-10-2013

Scottish stem cell companies Sistemic and Roslin Cells say they are working together with c to make the…

BiotechnologyEuropeGeneticsResearchRoslin CellsSistemic

arGEN-X R&D milestone triggers payment from Shire

19-09-2013

Belgium-based preclinical stage biotech firm arGEN-X has announced a key milestone in its SIMPLE Antibody…

arGEN-XBiotechnologyEuropeFinancialGenetics

US regenerative medicine market to increase at a CAGR of 15.8%

03-09-2013

The US regenerative medicine market has been forecast to increase at a compound annual growth rate (CAGR)…

BiotechnologyGeneticsMarkets & MarketingNorth America

Potential Duchenne drug expected to complete phase III trial this year

16-08-2013

Dutch biotech company Prosensa says it has made progress with its Duchenne treatments, with six exon…

drisapersenEuropeGeneticsGlaxoSmithKlinePharmaceuticalProsensaResearch

Stem cell company ReNeuron gets backing from Welsh government

22-07-2013

UK-based stem cell company ReNeuron (AIM: RENE) will relocate to Wales after Arthurian Life Sciences,…

BiotechnologyEuropeFinancialGeneticsReNeuron

Genomics England's priorities announced on 65th anniversary of the UK's NHS

05-07-2013

The chief executive of the Association of the British Pharmaceutical Industry (ABPI) has welcomed the…

GeneticsPharmaceutical

Next generation sequencing market expected to grow to $2.7 billion by 2017

04-07-2013

The next generation sequencing (NGS) market has been forecast to increase at a compound annual growth…

BiotechnologyEuropeGeneticsIlluminaMarkets & MarketingNorth America

US Supreme Court issues mixed ruling on DNA patents

14-06-2013

The US Supreme Court yesterday (June 13) delivered its unanimous decision regarding the Association for…

BiotechnologyGeneticsLegalMyriad GeneticsNorth AmericaPatents

Genetics and genomics industry in the USA has a trillion dollar impact, new Battelle study shows

14-06-2013

A new Battelle study released this week by United for Medical Research illustrates the genetics and genomics…

BiotechnologyFinancialGeneticsNorth AmericaResearch

Merger between Intercell and Vivalis planned to complete soon

14-05-2013

French biotech firm Vivalis (Euronext: VLS) previously-announced acquisition of Intercell (ICEL.VI) in…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Treatment with old drug suramin corrects autism symptoms in mouse model

14-03-2013

Testing a new theory, researchers at the University of California, San Diego School of Medicine have…

GeneticsMetabolicsPharmaceuticalResearch

Ethris enters SNIM modified RNA alliance with Shire

07-01-2013

German biotech firm Ethris GmbH has initiated a research based alliance focused on the development and…

BiotechnologyEthris GmbHGeneticsLicensingPharmaceuticalResearchShire

Vivalis and Intercell announce "merger of equals"

18-12-2012

French biotech firm Vivalis (Euronext: VLS) has entered into an accord to acquire Intercell (ICEL.VI)…

BiotechnologyIntercellMergers & AcquisitionsVaccinesValnevaVivalis

Vivalis in new EB66 cell line deal with Merial

18-07-2012

France-based Vivalis (NYSE Euronext: VLS) announced today that it has executed a new research license…

EB66LicensingMerialPharmaceuticalSanofiVaccinesVivalis

EU funds Population Genetics in leukemia study consortium

28-05-2012

The largest ever genomic study of relapsed acute lymphoblastic leukemia (ALL), the most common malignant…

FinancialGeneticsOncologyPharmaceuticalPopulation Genetics TechnologiesResearch

Emerging discoveries offer opportunities for uncommon genetic disorders

22-05-2012

Groundbreaking therapies are on the horizon as scientists explore new treatment options for rare genetic…

BiotechnologyGeneticsMarkets & MarketingPharmaceuticalResearch

Vivalis signs another EB66 out-licensing deal for MAb production

14-03-2012

French biotech firm Vivalis (NYSE Euronext: VLS) has signed a joint collaboration and commercial license…

BiotechnologyEB66LicensingVaccinesVivalis

Vivalis opens new lab for antibody discovery; posts 112% revenue hike

25-01-2012

French biotech firm Vivalis (NNYSE Euronext: VLS) says it has opened a new facility for partnered VIVA|Screen…

BiotechnologyEuropeFinancialResearchSanofi PasteurVivalis

Sanofi Pasteur and Vivalis extend MAb accord

19-01-2012

French biopharma company Vivalis (NYSE Euronext: VLS) says it has extended the agreement signed in 2010…

Antibiotics and Infectious diseasesLicensingPharmaceuticalResearchSanofiSanofi PasteurVivalis

1 to 25 of 28 results

Back to top